tbuckley/cabot-search huggingface dataset:
Abstract 16725: Family History of Cardiovascular Disease is an Independent Predictor of Gestational Hypertensive Disease and Diabetes: The Korean Nurses’ Survey
Authors: Heesun Lee, Chang-Hwan Yoon, Hyun-Young Park, Hea Young Lee, Dong-Ju Choi, Myeong Chan Cho
Journal: Circulation (2014)

Background: Gestational hypertensive disorders and diabetes are well-known to increase the risk of cardiovascular disease (CVD) and diabetes later in life. However, there were few researches to evaluate the association between family history of cardiovascular disease and the occurrence of pregnancy-related medical disorders. We aimed to investigate whether family history of CVD could predict gestational hypertensive disorders and diabetes. Methods: The Korean Nurses’ Survey was conducted through web-based computer-assisted self-administered questionnaires, which were compiled by consultation to cardiologists, gynecologists, and statisticians, from October to December 2011. We enrolled a total of 9,989 female registered nurses who could answer reliably the questionnaires based on their medical knowledge. Multivariate logistic regression analysis was used to clarify the effect of family history of CVD on pregnancy-related medical disorders. Result: In this survey, 3900 subjects had more than 1 pregnancy. Among them, 247 interviewees (6.3%) had experienced hypertensive disorders during pregnancy, which included preeclampsia (n = 160, 4.1%) and transient hypertension (n = 144, 3.7%), and 120 (3.1%) had experienced gestational diabetes. And, 2872 subjects (73.6%) answered that they had at least 1 family history of CVD. Having family history of CVD increased the risk of gestational hypertensive disorders (adjusted RR 1.51, 95% CI 1.08-2.11, p = 0.015) and diabetes (adjusted RR 2.40, 95% CI 1.38-4.17, p = 0.002). In particular, family history of hypertension was significantly associated with gestational hypertensive disorders (adjusted RR 2.00, 95% CI 1.47-2.50, p &lt;0.001), and diabetes was highly related with gestational diabetes (adjusted RR 3.37, 95% CI 2.35-4.83, p &lt;0.001), respectively. Furthermore, this relationship was observed regardless of maternal parity. Conclusion: Family history of CVD was a significant predictor of pregnancy-related medical disorders in this survey. Meticulous history taking for family history of CVD can provide the risk of gestational hypertensive disease and diabetes. Thus, special attention should be paid to women with family history of CVD during pregnancy.
Abstract 13013: The Impact of Prolonged Clopidogrel Beyond 12 Months After Coronary Stenting in Patients with Acute Coronary Syndromes
Authors: Neil J Wimmer, Kyle Smoot, Kelly Cho, Galina Sokolovskaya, David Gagnon, Samantha Ly, Sara Temiyasathit, Jacquelyn Do, Adrianna Nava, Simon Ostrowski, J. M Gaziano, David P Faxon, Scott Kinlay
Journal: Circulation (2014)

Introduction: Clopidogrel up to 12 months after an acute coronary syndrome (ACS) lowers the risk of major adverse coronary events. Guidelines recommend clopidogrel for 12 months after coronary intervention (PCI) with bare-metal (BMS) or drug-eluting (DES) stents. The value of prolonging clopidogrel beyond 12 months in PCI patients with ACS is unknown. Hypothesis: We hypothesize that prolonged clopidogrel differentially reduces adverse events in patients receiving DES compared with those receiving BMS for an ACS. Methods: We linked all PCIs in the national Veterans Affairs (VA) health system from 2002-2006 with the VA pharmacy database. VA and non-VA clinical outcomes were identified by ICD9 codes from the VA and CMS/Medicare databases. All patients who were event free at 12 months were followed for death, myocardial infarction (MI), and recurrent target vessel revascularization (TVR). The hazard ratio for prolonged clopidogrel use (more than 12 months) versus clopidogrel for less than or equal to 12 months was assessed for each outcome within each stent type, using Cox proportional hazards models. Multivariable models and propensity models were also used to adjust for confounding related to the propensity for prolonged clopidogrel treatment. Results: After exclusions, 28,507 patients had PCI and were event free at 12 months. Of these, 18,279 (64%) had an ACS at their index PCI including 9,336 (51%) who received a DES and 8,447 (46%) who received prolonged clopidogrel. Events occurring up to 4 years after PCI in these ACS patients included 1358 deaths, 1885 death or MIs, and 1335 TVRs. Prolonged clopidogrel was associated with lower risk of death (interaction p=0.04) and death or MI (interaction p=0.001) only in patients receiving DES (Table). Similar results were seen in multivariable and propensity models. Conclusions: Prolonging clopidogrel more than 12 months after PCI for ACS may lower the risk of death or MI in patients receiving DES but not in patients receiving BMS.
Abstract 16646: Successful Expansion and Bioscaffolding of Clonogenic Cardiac Pericyte-Like Cells From Infants Affected by Congenital Heart Disease
Authors: Elisa Avolio, Iker Rodriguez-Arabaolaza, Somi Idowu, Jonathan Rowlinson, Helen Spencer, Federica Riu, Sadie Slater, Atsuhiko Oikawa, Mohamed Ghorbel, Massimo Caputo, Paolo Madeddu
Journal: Circulation (2014)

Introduction:  Current prostheses for correction of congenital heart disease (CHD) are unable to match the growth of an infant’s heart and deteriorate due to matrix degradation. Biological scaffolds integrated with progenitor cells able to grow and renew the prosthetic matrix may provide durable correction of CHD. We investigate the plasticity of cardiac pericyte-like cells obtained from CHD infants and their compatibility with a clinically certified prosthetic graft (CorMatrix).   Methods&Results:  CD34+ CD31- Pericytes (CPs) were immuno-sorted from myocardial specimen leftovers (n=13) of neonates and infants undergoing repairs of CHD. CPs were expanded and characterized for surface antigens, plasticity toward cardiovascular lineages, clonogenicity and ability to colonize a CorMatrix patch. We successfully expanded CPs in culture for several passages to reach a high number of cells (>20 million at P5). Flow cytometry of expanded cells at P4 (n=7) indicates a mesenchymal phenotype (CD105, CD44, CD90) but very low expression of endothelial and hematopoietic markers. Fluorescent microscopy of CP lines (n=6) show abundant expression of pericyte (NG2, vimentin, PDGFR-β) and stemness markers (Oct-4, SOX-2, Nanog). By single-cell sorting, we demonstrated the clonogenic capacity of CPs. When cultured with differentiation media, CPs failed to acquire mature endothelial proteins (VEGFR2, vWF, VE-Cadherin), while they acquired markers of synthetic VSMCs (α-SMA, Calponin, non-muscle myosin B, RBP1). Moreover, when grown under cardiomyocyte inductive conditions, CPs acquired TBX5, CACNA1C and Connexin43 at the transcriptional level. Finally, we succeed in growing CPs on a CorMatrix membrane. Fluorescent microscopy showed vimentin-positive CPs not only at the surface, but also within the patch, indicating ability to colonize, grow and form a cellularized scaffold.   Conclusions:  We show for the first time the possibility of expanding a clonogenic population of bona fide pericytes from hearts of CHD patients, differentiating them in cardiovascular cells, and growing them within extracellular matrices that are currently used in cardiac surgery. These data open new avenues for cellular functionalization of prosthetic material to correct CHD.
Looking up: Recent advances in understanding and treating peritoneal carcinomatosis
Authors: Laura A. Lambert
Journal: CA A Cancer Journal for Clinicians (2015)

Answer questions and earn CME/CNE Until recently, a diagnosis of peritoneal carcinomatosis was uniformly accompanied by a grim prognosis that was typically measured in weeks to months. Consequently, the management of carcinomatosis revolves largely around palliation of symptoms such as bowel obstruction, nausea, pain, fatigue, and cachexia. A prior lack of effective treatment options created the nihilistic view that currently exists and persists despite improvements in the efficacy of systemic therapy and the evolution of multimodality approaches including surgery and intraperitoneal chemotherapy. This article reviews the evolution and current state of treatment options for patients with peritoneal carcinomatosis. In addition, it highlights recent advances in understanding the molecular biology of carcinomatosis and the focus of current and future clinical trials. Finally, this article provides practical management options for the palliation of common complications of carcinomatosis. It is hoped that the reader will recognize that carcinomatosis is no longer an imminent death sentence and that through continued research and therapeutic innovation, clinicians can make an even greater impact on this form of metastatic cancer. CA Cancer J Clin 2015;65:283–298. © 2015 American Cancer Society.
Gynecological Aspects of Obstetrical Delivery
Authors: M L MCCALL
Journal: JAMA (1963)

Parturition should be looked upon as a physiological exercise, and ideally the multiparous state should be one of asymptomatic change associated with comfortable function. However, because obstetrics is a field in which serious complications may suddenly occur, the ideal is not always possible. Among the delayed effects of delivery is a group of gynecological complications which may affect the well-being of the woman so involved in later life. Such complications as uterine prolapse, cystocele, rectocele, enterocele, and genital fistula may be the grim aftermath of poor obstetric practice.The article reviews some of the advances in the prevention of maternal mortality and morbidity and emphasizes the important place of intelligent conservative obstetrics in the hands of both general physicians and specialists.
HERNIA OF THE DIAPHRAGM; REPORT OF TWO CASES
Authors: John H. Foster
Journal: Annals of Internal Medicine (1941)

Case Reports1 May 1941HERNIA OF THE DIAPHRAGM; REPORT OF TWO CASESJOHN H. FOSTER, M.D., F.A.C.P.JOHN H. FOSTER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-14-11-2125 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough an increased number of cases of hernia of the diaphragm is being recorded, it may be still regarded as a rare condition. A great number of types and varieties and degrees of hernia have been recognized and various attempts at classification have been made, based on anatomy, embryology, etiology, and contents, but it is impossible to distinguish these clinically. Perhaps the most satisfactory method is to consider these all as (1) traumatic or (2) non-traumatic. The traumatic may be divided into (A) indirect, injury resulting from a crushing blow to the chest or abdomen; (B) direct, the result of...Bibliography1. HEDBLOM CA: Hernia of the diaphragm, Cycl. of Med., 1932, iv, 553. Google Scholar2. STOBIE GH: Diaphragmatic hernia (a review of recent literature and report of five cases), Canad. Med. Assoc. Jr., 1937, xxxvi, 136. Google Scholar3. MARKS JH: Diaphragmatic hernia and associated conditions, Am. Jr. Roentgenol., 1937, xxxvii, 613. Google Scholar4. HARRINGTONKIRKLIN SWBR: The clinical and roentgenological manifestation and surgical treatment of diaphragmatic hernia, with a review of 131 cases, Radiology, 1938, xxx, 147. CrossrefGoogle Scholar5. ROOTPRITCHETT JCCP: Diaphragmatic hernia, Cleveland Clin. Quart., 1938, v, 203. CrossrefGoogle Scholar6. TRUSDALE PE: Diaphragmatic hernia in children with a report of 13 cases, New Eng. Jr. Med., 1935, ccxiii, 459. Google Scholar7. BOWEN A: Diaphragmatic hernia; review of literature, Am. Jr. Surg., 1938, xxxix, 4. CrossrefGoogle Scholar8. Personal communication, Dr. J. L. Harvey, Roentgenologist, Waterbury Hospital. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Waterbury, Connecticut*Received for publication May 31, 1939.From the Medical Service of The Waterbury Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1941Volume 14, Issue 11Page: 2125-2137KeywordsEmbryologyEtiologyHerniaMedical servicesThorax ePublished: 1 December 2008 Issue Published: 1 May 1941 PDF downloadLoading ...
Statement of Retraction
Authors: Dan Ziegler
Journal: Diabetes Care (2008)

At least one of four diabetic patients is affected by distal symmetric polyneuropathy, which represents a major health problem, since it may present with partly excruciating neuropathic pain and is responsible for substantial morbidity, increased mortality, and impaired quality of life. Treatment is based on four cornerstones: 1) causal treatment aimed at (near)-normoglycemia, 2) treatment based on pathogenetic mechanisms, 3) symptomatic treatment, and 4) avoidance of risk factors and complications. Recent experimental studies suggest a multifactorial pathogenesis of diabetic neuropathy. From the clinical point of view, it is important to note that, based on these pathogenetic mechanisms, therapeutic approaches could be derived, some of which are currently being evaluated in clinical trials. Among these agents, only alpha-lipoic acid is available for treatment in several countries and epalrestat in Japan. Although several novel analgesic drugs such as duloxetine and pregabalin have recently been introduced into clinical practice, the pharmacologic treatment of chronic painful diabetic neuropathy remains a challenge for the physician. Individual tolerability remains a major aspect in any treatment decision. Epidemiological data indicate that not only increased alcohol consumption but also the traditional cardiovascular risk factors such as hypertension, smoking, and cholesterol play a role in development and progression of diabetic neuropathy and hence need to be prevented or treated.
Abstract 41: Incidence of Cardiovascular Emergencies During Cardiac Tests
Authors: Maria Margarita Gonzalez, Ivana Antelmi, Frederico J Mancuso, Valdir A Moises, Daniella B Kerbauy, Jeane M Tsutsui
Journal: Circulation (2014)

Background: Cardiovascular major events are infrequent during cardiac testing. In Brazil, cardiologic tests are performed in hospitals and outpatient diagnostic centers. One of the most important outpatient diagnostic centers in Sao Paulo, the most populous city in Brazil, is Fleury Medicine and Health (FMH). In average, 150 thousand cardiac tests are performed annually at FMH. Our objective was to analyze the incidence of cardiovascular emergencies during cardiac tests. Methods: During a 14-month period (January 2013 to February 2014), were prospectively collected all severe cardiovascular emergencies while performing cardiac tests at FMH. Serious cardiovascular emergencies were defined as those where the patient required transfer to hospital center to continue treatment. Results: During this period 172,567.00 cardiac tests were performed in FMH, from them, 43% correspond to exercise testing, 29% transthoracic echocardiograms and 26% electrocardiograms . Forty four cardiovascular emergencies were reporte...
Abstract 16779: A Novel Hydrogen Sulfide Donor Promotes Nitric Oxide Bioavailability in a Phase I Clinical Trial
Authors: David J Polhemus, Tony Giordano, David J Lefer
Journal: Circulation (2014)

Introduction: Recent studies suggest molecular crosstalk between hydrogen sulfide (H2S) and nitric oxide (NO), although the mechanisms remain poorly understood. Heart failure patients have been reported to be deficient of both H2S and NO, two molecules that are critical for cardiovascular homeostasis. A Phase I clinical trial of a highly novel H2S donor agent (SG-1002) sought to assess the safety of SG-1002 as well as the effects of this drug on H2S and NO bioavailability in healthy subjects. Methods: 7 healthy male subjects were given SG-1002 orally in dosages ranging from 200-800 mg/kg twice daily for 7d. Plasma samples were collected at incremental time points during a 24hr. period. H2S levels were determined using gas chromatography coupled with sulfur chemiluminescence (7890B and 355 SCD, Agilent Tech.). NO bioavailability was determined by measuring the NO intermediate, nitrite (NO2), using ion chromatography (ENO-30, EICOM USA). Results: Administration of SG-1002 at the 800 mg/kg, b.i.d. dosage in ...
A Milestone in Clinical Medicine: A Review of "The Clinical Approach to the Patient"
Authors: Chase Patterson Kimball
Journal: Annals of Internal Medicine (1970)

The Literature of Medicine1 February 1970A Milestone in Clinical Medicine: A Review of "The Clinical Approach to the Patient"CHASE PATTERSON KIMBALL, M.D.CHASE PATTERSON KIMBALL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-72-2-291 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMorgan and Engel's The Clinical Approach to the Patient* discusses patients and physicians and what goes on between them in relating to the patient's problem. This is not lip service about the bedside manner and the art of medicine but an objective and didactic study for students who want to learn an approach to illness as a human phenomenon. This volume suggests an innovative approach to disease and physical diagnosis by addressing itself to the methods of data collection by the physician and how these data are synthesized and integrated into concepts of illness and disease.This is a most...References1. WEED L: Medical records that guide and teach. New Eng J Med, 278:593, 652, 1968 CrossrefMedlineGoogle Scholar2. FEINSTEIN A: Clinical Judgment. Baltimore, The Williams & Wilkins Co., 1967 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Yale University New Haven, Conn.*MORGAN WL JR, ENGEL GL: The Clinical Approach to the Patient. W. B. Saunders Co., Philadelphia, 1969. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1970Volume 72, Issue 2Page: 291-293 ePublished: 1 December 2008 Issue Published: 1 February 1970 PDF downloadLoading ...
Abstract 11702: Atg7-dependent Regulation of P62 in Mice Ameliorates Desmin Related Cardiomyopathy
Authors: Md. Shenuarin Bhuiyan, J Scott Pattison, Jeanne James, James Gulick, Hanna Osinska, Jeffrey Robbins
Journal: Circulation (2012)

Background: Autophagy is a cellular homeostatic mechanism that can eliminate damaged and potentially toxic proteins. We have noted impaired autophagic activity in a mutant αB-crystallin (CryABR120G...
Abstract 9173: Neurological and Cardiac Functional Status After Extracorporeal Membrane Oxygenation in Children with Heart Disease
Authors: Saleh S Alshehri, Rakshay Shetty, Christopher A Caldarone, Colleen Gruenwald, Cedric Manlhiot, Brian W McCrindle, Steven M Schwartz, Glen S Van Arsdell, Venkatesan B Sivarajan
Journal: Circulation (2011)

Introduction: There are limited outcomes data following hospital discharge after extracorporeal membrane oxygenation (ECMO) in children with heart disease. Hypothesis: Children with heart disease who are hospital survivors of ECMO have ongoing mortality, but minimal functional residua. Methods: We reviewed data of all children with heart disease receiving venoarterial ECMO for a cardiac indication between 2001-2008. Pre-ECMO characteristics, ECMO details, complications and outcomes were abstracted from institutional databases and medical records. Univariate and multivariable analyses to determine factors associated with hospital survival and neurological outcomes using the Pediatric Cerebral Performance Category (PCPC) score were performed. Results: 184 ECMO episodes (163 patients) occurred at a median ( 25 th , 75 th %ile) age of 0.36 (0.04, 2.2) years; indications were cardiomyopathy (22%) and post-cardiotomy (66%). Cardiac arrest prompted 100 (54%) ECMO episodes in 86 patients. The median duration of CPR was 31 minutes. The median ECMO duration was 4 days. ECMO complications included intracranial hemorrhage (22%), ischemic brain injury (27%), seizures (27%), pulmonary or gastrointestinal bleeding (15%) and need for renal replacement therapy (49%). Of the total inception cohort, 63 (41%) survived to hospital discharge; 58 (36%) were alive at a median follow-up of 3.6 years with the majority (81%) having a PCPC score ≤ 2. Of the 86 patients who had cardiac arrest, 28 (33%) survived to hospital discharge; 22 (26%) were alive at a median follow-up of 3 years with the majority (81%) having a PCPC score ≤ 2. At follow-up, 55 (82%) were in pediatric NYHA Class ≤ 2 heart failure. Factors associated with hospital survival were cardiomyopathy (OR=2.2, p=0.01) and biventricular physiology (OR=1.9, p=0.006). A pre-ECMO diagnosis of cardiomyopathy was associated with a lower PCPC score at 6 months (EST: -0.24, p=0.0007), while ECMO for cardiac arrest was associated with a higher PCPC score at (EST: 0.16, p=0.008) 6 month follow-up. Conclusion: Children with heart disease who survive to hospital discharge after ECMO have ongoing early mortality; despite these concerns, survivors have good quality neurological outcome and cardiac functional status.
Response of angiogenic factors to the treatment with melatonin in breast cancer cell lines.
Authors: Bruna Victorasso Jardim, Marina Gobbe Moschetta, Thaiz Ferraz Borin, Gabriela Bottaro Gelaleti, Camila Leonel, Livia Carvalho Ferreira, Juliana Ramos Lopes, Larissa Bazela Maschio, Naiane do Nascimento Goncalves, Debora Aparecida Pires de Campos Zuccari
Journal: Journal of Clinical Oncology (2012)

120 Background: Tumor growth and metastasis are the leading cause of death in breast cancer patients. The tumor growth requires neoangiogenesis, stimulated by vascular endothelial growth factor (VEGF) expressed under control of hypoxia-inducible factor-1α (HIF-1α). Melatonin, a natural hormone has been suggested as a new therapeutic agent to inhibit angiogenesis factors in several types of cancers. We evaluated the HIF-1α and VEGF expression in breast cancer cell line after hypoxia and treatment with melatonin. Methods: Breast cancer cell lines ER-positive (MCF-7) and ER-negative (MDA-MB-231) were cultured in DMEM at 37°C in 5% CO2. The cells were treated with CoCl2 to mimic hypoxia, and then treated with melatonin. Cell viability was measured by MTT assay with five melatonin concentrations (0.5mM, 1mM, 2mM, 5mM, 10mM). For the pharmacological concentration of melatonin (1mM) the protein and gene expression of HIF-1α and VEGF were detected by immunocytochemistry and real time PCR, respectively. Results: There was a significantly decrease in MCF-7 cells viability after treatment with all concentrations of melatonin and in MDA-MB-231 cells just with 1mM (p&lt;0.05). The melatonin treatment did not alter the protein and gene expression of HIF-1α in MCF-7 cells (p&gt;0.05), however, it significantly decreased the VEGF protein expression (p&lt;0.05). In MDA-MB-231 cells there was significant decreased in the HIF-1α protein expression (p&lt;0.05). Conclusions: Our results showed that 1mM of melatonin decreased the cell viability and HIF-1α protein expression in ER-negative cells, and VEGF protein expression in ER-positive cells. This study is the first that evaluated the expression of these angiogenic factors in breast cancer cells after treatment with melatonin that can be a potential therapeutic agent. Thus, we are performing in vivo study to confirm the potential effectiveness of melatonin in the control of angiogenesis in breast cancer.